首页 >
法规速递
-
Document: European Medicines Agency post-authorisation procedural advice for users of the centralised procedure-2025/12/15
2025-12-16查看详情 > -
Page: Quality of medicines questions and answers: Part 2-2026/1/28
2026-01-29查看详情 > -
Document: Opinion of the CVMP on the establishment of maximum residue limits: Lidocaine (EMEA/V/MRL/003649/MODF/0004)-2026/3/6
2026-03-09查看详情 > -
Document: Notices and alerts per role - CTIS Training Programme - Module 07-2026/4/7
2026-04-08查看详情 > -
Hypertension Indication: Drug Labeling for Cardiovascular Outcome Claims (Final)-2022/12/15
2022-12-16查看详情 > -
关于公开征求《患者报告结局指标用于风湿免疫性疾病临床试验的技术指导原则》意见的通知-2023/6/27
2023-06-27查看详情 > -
Draft Guidance for Industry: Master Protocols for Drug and Biological Product Development-2023/12/21
2024-01-03查看详情 > -
中药保护品种公告（第23号）（2025年第11号） -2025/1/24
2025-01-24查看详情 > -
Document: Annex - National provisions for SMEs applicable to the pharmaceutical sector-2025/2/26
2025-02-27查看详情 > -
Page: Real-world evidence-2025/4/3
2025-04-07查看详情 >
